Healthcare | November 25, 2021
Boehringer Ingelheim India enters Guinness World Records through its Stroke campaign
The week-long campaign received a record 17.691 pledges
The week-long campaign received a record 17.691 pledges
Arrowhead to receive US $ 120 million upfront payment for Phase 1/2 program for NASH and is eligible to receive potential milestone payments and royalties on commercial sales
The programme will be implemented across 13 states and benefit 256 min
The approval is for Cytomegalovirus, a type of Herpes virus
Dabigatran Etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE)
Hospitals and outpatient clinics can also digitally navigate patients from the time an order is placed, to when it is scheduled and completed through follow-up
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
The final data from the trial showed sotrovimab reduces hospitalisation and risk of death by 79% in adults with mild-to-moderate Covid-19 who are at high risk of progression to severe disease
Subscribe To Our Newsletter & Stay Updated
